IP Library Granted Patent US 10,323,040
Granted Patent B2
US 10,323,040 · App. 15/248,553 · Granted Jun 18, 2019

Process for the preparation of 5-fluorotryptophol

Inventors: Stefan Pruehs (Neuss, DE); Olaf Schaefer (Stolberg, DE)
Assignee: GRUENENTHAL GMBH
C07D491/107C07D209/12C07D209/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,323,040
App. No.
15/248,553
Granted
Jun 18, 2019
Kind
B2
Abstract

The present invention relates to a process for the preparation of 5-fluorotryptophol as well as a process for the preparation of (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4b]-indol]-4-amine using the 5-fluorotryptophol obtained by said first process. The process according to the invention provides 5-fluorotryptophol in improved yield and purity without the need for chromatographic purification of the product.

Claims (32)

1. A process for preparing 5-fluorotryptophol comprising steps of

a) providing a mixture comprising 4-fluorophenyl-hydrazine, an activation reagent, water and at least one aprotic organic solvent selected from the group consisting of tetrahydrofuran, 2-methyltetrahydrofuran and isopropyl acetate;

b) adding to the mixture a solution of at the most about 1.1 equivalents of 2,3-dihydrofuran in at least one aprotic organic solvent selected from the group consisting of tetrahydrofuran, 2-methyltetrahydrofuran and isopropyl acetate to react with the 4-fluorophenylhydrazine to give 5-fluorotryptophol, wherein the aprotic solvent and water provided in steps a) and b) are provided in a ratio relative to each other such that a heterogeneous reaction mixture comprising a liquid organic phase and a liquid aqueous phase is formed either before or during addition step b);

c) separating the organic from the aqueous phase;

d) contacting the organic phase with an aqueous solution of at least one inorganic salt to form a heterogeneous mixture comprising a liquid organic phase and a liquid aqueous phase;

e) separating the organic phase from the aqueous phase of the heterogeneous mixture; and

f) isolating 5-fluorotryptophol from the organic phase via a precipitation step.

2. The process according to claim 1 , wherein the mixture formed in step a) is a heterogeneous mixture comprising a liquid organic phase and a liquid aqueous phase.

3. The process according to claim 1 , wherein the activation reagent is at least one protic acid or a heterogeneous Bronsted acid catalyst.

4. The process according to claim 1 , wherein the activation reagent is

a) a protic acid in an amount of at least one equivalent relative to the 4-fluorophenylhydrazine or

b) a catalytic amount of a heterogeneous Bronsted acid catalyst.

5. The process according to claim 1 , wherein the activation reagent is a protic acid that has a pK a -value in the range of −6.5 to +10.

6. The process according to claim 5 , wherein the protic acid is added to the reaction medium in the form of its addition salt with 4-fluorophenylhydrazine.

7. The process according to claim 1 , wherein the activation reagent is HCl.

8. The process according to claim 1 , wherein the activation agent is a mixture of one equivalent relative to 4-fluorophenylhydrazine of an acid selected from the group consisting of HCl, HBr, H 2 SO 4 , H 3 PO 4 and HClO 4 and an additional amount of a second acid selected from the group consisting of NH 4 Cl, NH 4 HSO 4 , (NH 4 ) 2 SO 4 , (NH 4 )H 2 PO 4 , (NH 4 ) 2 HPO 4 , and (NH 4 ) 3 PO 4 .

9. The process according to claim 8 , wherein the second acid is NH 4 Cl.

10. The process according to claim 1 , wherein the activation reagent is a catalytic amount of a heterogeneous Bronsted acid catalyst selected from the group consisting of Amberlyst-15, Amberlite-120, Indion-130, Montmorillonite K10 and Zeolite HY.

11. The process according to claim 1 , wherein the aprotic organic solvent is selected from the group consisting of isopropyl acetate and 2-methyltetrahydrofuran or mixtures thereof.

12. The process according to claim 1 , wherein water and the aprotic organic solvent are present in the heterogeneous reaction medium at a volume ratio of from about 1:3 to about 3:1.

13. The process according to claim 1 , wherein the reaction in step (b) is carried out at a temperature of at least about 50° C.

14. The process according to claim 1 , wherein phase separation step (c) is carried out at elevated temperatures in a range between 40° C. to 60° C.

15. The process according to claim 1 , wherein the formation of the heterogeneous mixture in step (d) is carried out at elevated temperatures in a range between 40° C. to 60° C.

16. The process according to claim 1 , wherein phase separation step (e) is carried out at elevated temperatures in a range between 40° C. to 60° C.

17. The process according to claim 1 , wherein isolation step (f) comprises steps of

f1) removal of the aprotic organic solvent from the organic phase obtained in step (e) to give a residue;

f2) adding to the residue obtained in step f1) water or an aqueous solution of at least one inorganic salt and an organic solvent having a water solubility at 20° C. below 5 g/l to form a heterogeneous mixture comprising a liquid aqueous phase and a liquid organic phase;

f3) separating the liquid organic phase from the heterogeneous mixture obtained in step f2); and

f4) precipitating the 5-fluorotryptophol from the liquid organic phase obtained in step f3).

18. The process according to claim 17 , wherein the organic solvent added in step f2) is toluene or benzene.

19. The process according to claim 17 , wherein the formation of the heterogeneous mixture in step f2) and/or the separation of the liquid organic phase in step f3) are/is carried out at elevated temperatures in a range from 40° C. to 60° C.

20. The process according to claim 1 , wherein in step b) relative to 4-fluorophenylhydrazine about 0.9 to 1.1 equivalent of 2,3-dihydrofuran are added to the heterogeneous reaction mixture.

Assignments (4)
CHANGE OF NAME Recorded May 21, 2025
From: PARK THERAPEUTICS, INC.
To: ADNEURIS THERAPEUTICS, INC.
Reel/Frame 071349/0825 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNMENT PREVIOUSLY RECORDED PREVIOUSLY RECORDED AT REEL: 068713 FRAME: 0499. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 24, 2024
From: TRIS PHARMA, INC.; PARK THERAPEUTICS, INC.
To: PROVIDENT BANK
Reel/Frame 070760/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2021
From: GRÜNENTHAL GMBH
To: PARK THERAPEUTICS, INC.
Reel/Frame 057212/0157 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2016
From: PRUEHS, STEFAN; SCHAEFER, OLAF
To: GRUENENTHAL GMBH
Reel/Frame 040186/0435 →
Priority Claims (1)
EP 14000696.6 · Feb 27, 2014 · regional
Continuity (2)
Continuation PCTEP2015000441 · Feb 26, 2015
Related Publication 20160362417A1 · Dec 15, 2016